Pfizer unveils positive results for Prevnar 20, Comirnaty booster coadministration

By NS Healthcare Staff Writer

13 Jan 22

In the Phase 3 study, PREVNAR 20 vaccine triggered similar responses for all 20 serotypes, either with Pfizer-BioNTech…

PharmaceuticalsClinical trials

Medicago, GSK unveil positive results for plant-based Covid-19 vaccine candidate

By NS Healthcare Staff Writer

08 Dec 21

The vaccine showed 71% overall efficacy against all variants of SARS-COV-2, and 75.6% in people who were not…

PharmaceuticalsClinical trials

AstraZeneca, Moderna’s AZD8601 meets primary endpoint in Phase 2 EPICCURE trial

By NS Healthcare Staff Writer

16 Nov 21

AZD8601 is an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A), jointly developed by AstraZeneca and…

PharmaceuticalsClinical trials

Covaxin shows 77.8% efficacy against Covid-19: Lancet Study

By NS Healthcare Staff Writer

12 Nov 21

The 77.8% vaccine efficacy was based on 130 confirmed cases, where 24 cases were observed in the vaccine…

PharmaceuticalsClinical trials

Gilead, Merck begin Phase 2 study of investigational HIV treatment regimen

By NS Healthcare Staff Writer

27 Oct 21

The regimen includes Merck’s nucleoside reverse transcriptase translocation inhibitor islatravir and Gilead’s potential capsid inhibitor lenacapavir

PharmaceuticalsClinical trials

Novartis’ cancer drug canakinumab fails in Phase 3 CANOPY-1 trial

By NS Healthcare Staff Writer

26 Oct 21

The Phase 3 CANOPY-1 study did not meet its primary endpoints of OS and PFS in patients with…

PharmaceuticalsClinical trials

Moderna’s Covid-19 vaccine found effective in kids aged six to 11 years: Study

By NS Healthcare Staff Writer

26 Oct 21

In the Phase 2/3 study, two 50μg doses of mRNA-1273 were generally well tolerated and showed superior neutralising…

PharmaceuticalsClinical trials

Biological E seeks DGCI approval to study Corbevax as booster dose

By NS Healthcare Staff Writer

13 Oct 21

Corbevax is an RBD protein sub-unit vaccine currently under Phase 2/3 clinical trials in adults aged 18 years…

PharmaceuticalsClinical trials

Merck’s molnupiravir reduces risk of Covid-19 hospitalisation or death by half

By NS Healthcare Staff Writer

04 Oct 21

Merck intends to pursue the US FDA emergency use authorisation for the drug, and file regulatory applications with…

PharmaceuticalsClinical trials

Sanofi halts development of mRNA-based Covid-19 vaccine

By NS Healthcare Staff Writer

29 Sep 21

The company will focus on the development of adjuvanted recombinant vaccine candidate, in partnership with GlaxoSmithKline (GSK)

PharmaceuticalsClinical trials